Incyte Corp (NASDAQ:INCY)

Bull and Bear

Top Analyst Upgrades and Downgrades: Exxon, Home Depot, Lululemon, 3M, Vodafone, Mondelez, Chevron and More

Stocks were marginally lower on Monday to kick off the week, after the prior week was in the red. The one trend that is nearly four years old is that ...
Read Full Story »
biotech

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

There should be no surprise to biotech investors that the mergers and acquisition (M&A) market and chatter are heating up. The huge buy of Synageva Biopharma Corp. (NASDAQ: GEVA) by ...
Read Full Story »
Pills

The Next 3 Likely Biotech Buyout Candidates

One good way for a company to increase sales and move past simple organic growth is to make an acquisition, and that is just what AbbVie Inc. (NYSE: ABBV) did ...
Read Full Story »
Perfume image

Insider Selling Remains Choppy as Stock Market Grinds Higher

In a trend that seems somewhat locked into place, like the horrible winter weather in the Northeast, insiders continue to sell stock, though as we have seen most of this ...
Read Full Story »
DNA

Has Agenus Run Too Much?

Agenus Inc. (NASDAQ: AGEN), in conjunction with Incyte Corp. (NASDAQ: INCY), announced a global license for the development and commercialization of Agenus’s proprietary Retrocyte Display antibody discovery platform. As a ...
Read Full Story »
fda_logo

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks. These events refer to reviews and decisions by the U.S. Food ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Aegerion, Avon, Atmel, LinkedIn, Ocwen, Visa and More

Stocks screamed higher on Friday on a surprise Japan expansion of its own stimulus and quantitative easing measures. Investors have proved, even during October, that they are willing to buy ...
Read Full Story »
biotech

Analyst Sees Incyte Worth 70% More

Incyte Corp. (NASDAQ: INCY) has serious upside potential, but the inherent risk within it may be too much for some investors to bear. This stock is not for the risk ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

Stocks were firm on Wednesday morning ahead of the FOMC meeting outcome. Tuesday's rally may have sparked higher interest again, and investors are looking for bargains now that stocks are still ...
Read Full Story »
Biotechnology word cloud

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

The firms we cover on Wall Street are sometimes like covering the major sports teams. Analysts are like the top players and tend to move around as their career strengths ...
Read Full Story »
Biotechnology word cloud

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

After the biotech stocks were absolutely crushed in the late winter and early spring, many of the top firms we cover on Wall Street were aggressive in their calls to ...
Read Full Story »
research

Three Companies That Want to Cure Pancreatic Cancer

Within 20 years cancer is expected to be the number one killer of people in the United States. While many cancers are survivable with chemotherapy and radiation, one that ...
Read Full Story »
DNA

Top Biotech Stocks for Cancer Cures From Cowen

The conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Buffalo Wild Wings, Coca-Cola, DSW, Intuitive Surgical and More

As earnings season continues to roll on, investors are keeping a close eye not only on the final results for the first quarter, but how those results are being interpreted. ...
Read Full Story »
DNA

UBS Top Stocks to Buy Working for Cancer Cures

Cancer is the leading cause of death globally, and a disease that touches almost every person in our nation one way or another. In a new research report, the Healthcare ...
Read Full Story »